T he primary goal of treatment in patients with chronic hepatitis C virus (HCV) infection is to achieve a sustained virologic response (SVR). SVR is defined as undetectable serum HCV RNA (Ͻ50 IU/mL), as measured by a sensitive polymerase chain reaction assay, 24 weeks after the end of treatment. Achievement of an SVR in patients with chronic hepatitis C has been associated with improvements in liver histology and healthrelated quality of life, as well as a reduced risk of hepatocellular carcinoma and liver-related mortality. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The combination of pegylated interferon (peginterferon) plus ribavirin is the treatment of choice for patients with chronic HCV infection. [12] [13] [14] [15] Peginterferon alfa-2a in combination with ribavirin has produced overall SVR rates of up to 66% in HCV mono-infected patients 16 -18 and 50% in patients with human immunodeficiency virus (HIV)-HCV coinfection. 19, 20 However, limited data exist regarding the long-term durability of an SVR following peginterferon treatment for chronic hepatitis C. An SVR achieved with conventional interferon alfa therapy has been shown to be durable. 9, 10, [21] [22] [23] In this long-term follow-up study of a large cohort of patients originally enrolled in clinical trials, we aimed to quantify the long-term durability of SVR following treatment with peginterferon alfa-2a administered alone or in combination with ribavirin. The analysis includes a broad range of patients with chronic hepatitis C from randomized phase 3 clinical trials. Patients enrolled included HCV mono-infected patients treated with peginterferon alfa-2a at a range of doses, either alone or in combination with ribavirin also at a range of doses, as well as patients with persistently "normal" alanine aminotransferase (ALT) levels and those with HIV-HCV coinfection.
Patients and Methods
Patients were eligible for the long-term follow-up study if they were previously enrolled in one of 10 clinical trials. 16,17,20,24 -30 Patients were not eligible for inclusion in the longterm follow-up study if they had been treated with anti-HCV therapy other than those medications assigned in the original protocol since enrolling in the original trials; were unable or unwilling to provide informed consent or abide by the requirements of the study; and had a history or other evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator, unsuitable for the study.
Safety Population
All patients enrolled in the long-term follow-up study were included in the safety population if they had at least one postbaseline safety assessment.
The primary safety end point was defined as the percentage of patients with significant clinical events postbaseline including deaths, liver transplantation, symptoms of decompensated liver disease (ascites, variceal bleeds), presence of encephalopathy or ascites, or hepatic malignancies.
Efficacy Population
Patients were eligible for inclusion in the efficacy analysis if they had undetectable serum HCV RNA (Ͻ50 IU/mL) at their last assessment in one of 9 trials (Figure 1 ): 3 randomized multicenter trials of peginterferon alfa-2a (PEGASYS; Roche, Basel, Switzerland) monotherapy 26, 27, 29 and 6 randomized multicenter trials of peginterferon alfa-2a plus ribavirin (COPEGUS; Roche, Basel, Switzerland). 16, 17, 20, 25, 28, 30 Details of the patient populations and treatment regimens for each of the 9 clinical trials have been reported in full elsewhere. All of the studies were conducted in treatment-naive patients with chronic hepatitis C infection. One trial included only patients with cirrhosis or bridging fibrosis. 26 One trial was conducted exclusively in patients with persistently normal ALT levels, defined as ALT activity equal to or below the upper limit of normal documented on at least 3 occasions a minimum of 4 weeks apart, with at least one value obtained during the 42-day screening period and at least one value obtained 6 to 18 months before screening. 30 The AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT) included only patients with HIV-HCV coinfection. 20 Peginterferon alfa-2a was dosed at 180 g/wk except in 2 of the monotherapy trials. In one of these trials, it was also dosed at either 90 g/wk 26 or 135 g/wk, 27 and in the trial by Fried et al 25 in patients with HCV genotype 1, a high viral load, and body weight Ͼ85 kg, it was dosed at 270 g/wk. In the combination therapy trials, ribavirin was dosed at a fixed dosage of 800 mg/day 17, 20, 28, 30 or a weight-adjusted dosage of 1000 or 1200 mg/day in patients with body weight Ͻ75 kg or Ն75 kg, respectively, 16, 17 or at 1200 mg/day or 1600 mg/day in patients with body weight Ն85 kg 25 (Figure 1 ).
In this prospective trial, annual serum HCV RNA testing was performed at a centralized laboratory for approximately 5 years from the date of last treatment in the original study using the COBAS AMPLICOR HCV Test v2.0 (limit of detection of 50 IU/mL).
The study was approved by all institutional review boards, all patients provided written informed consent, and the study was conducted in full conformance with the principles of the Declaration of Helsinki or with the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual.
Results
This long-term follow-up study recruited 1753 patients from 198 centers in 19 countries. The first patient was enrolled in May 2000, and the last patient's final visit was in February 2008.
Safety Analysis
Of the 1753 patients who were recruited into the study, 17 patients did not have any demographic information; thus, a total of 1736 patients were enrolled. Of the 1736 patients enrolled, 12 had no postbaseline safety data; thus, the safety population comprised 1724 patients. The safety population included both treatmentnaive and treatment-experienced patients who were previously treated with conventional interferon with or without ribavirin or with peginterferon alfa-2a with or without ribavirin.
A total of 21 patients (1.2%) reported 25 significant clinical events during follow-up. One case of ascites (slight) and 4 cases of ascites (moderate) were reported. Four cases of encephalopathy (one case of grade 1 or 2 and 3 cases of grade 3 or 4) and one case of hepatic malignancy were reported. A total of 15 patients died during follow-up. Causes of death were gunshot wound (1), brain neoplasm (1), lung neoplasm (2), pancreatic carcinoma (1), road traffic accident (1), hepatic neoplasm (2), hepatitis C (1), non-Hodgkin's lymphoma (1), hematemesis (1), cerebrovascular accident (1), diffuse large B-cell lymphoma (1), cardiac disorder (1), and non-small cell lung cancer (1).
Efficacy Analysis: All Patients Enrolled
Of the 1736 patients enrolled, 1546 patients (89.1%) had undetectable HCV RNA at the last visit of their original study and at least one HCV RNA assessment postbaseline in the long-term follow-up study and thus were considered HCV RNA evaluable. The majority of patients (98.7% [1527/1546]) continued to have undetectable HCV RNA a mean of 4 years after the end of treatment in the original studies. Patients with recurrence of HCV RNA during follow-up included 5 patients previously treated with interferon alfa-2b plus ribavirin (one of whom did not have an SVR in the original study) and 14 patients previously treated with peginterferon alfa-2a with or without ribavirin (2 of whom did not have an SVR in the original study).
Efficacy Analysis: Patients Previously Treated With Peginterferon Alfa-2a With or Without Ribavirin
The primary efficacy analysis is restricted to a subset of treatment-naive patients treated with peginterferon alfa-2a with or without ribavirin. Treatment-experienced patients and patients treated with conventional interferon were excluded, as were patients with detectable HCV RNA at the end of their parent trial. Out of the 9 trials, 1344 patients who were serum HCV RNA negative at the last assessment in their original study were included in this analysis. One patient with no postbaseline HCV RNA evaluation was excluded from the analysis as defined in the protocol. A further 2 patients with recurrence of HCV RNA during long-term follow-up were included in the overall population but not included in the total of patients with recurrence of HCV RNA; although they had a negative HCV RNA at their last assessment in the original study, they did not have an SVR defined as HCV RNA negative (Ͻ50 IU/ mL) 24 weeks after an untreated follow-up period.
Of the 1343 patients with at least one postbaseline HCV RNA evaluation, 166 mono-infected patients received peginterferon alfa-2a monotherapy and 1077 received the combination of peginterferon alfa-2a and ribavirin. This latter group included 79 patients with normal ALT levels before undergoing treatment. A further 100 HIV-HCV coinfected patients received peginterferon alfa-2a with or without ribavirin. The clinical characteristics of the patients enrolled and the mean duration of follow-up are shown in Table 1 .
Patients from 7 of the 9 studies included in the present analysis completed the long-term follow-up study. Patients from 2 of the original studies were still enrolled in the long-term follow-up study when the sponsor terminated the study. The disposition of the patients from the completed studies is summarized in Table 2 . The most common reason for failing to complete the long-term follow-up was loss to follow-up.
Overall, 1331 of 1343 patients (99.1%) treated with peginterferon alfa-2a remained HCV RNA negative in serum after a mean follow-up of 3.9 years (range, 0.8 -7.1 years) ( Table 1 and Figure 2 ). Excluding the 12 patients with confirmed reversion to an HCV RNA-positive state, transient low levels of HCV RNA at single time points were detected in some serum samples during follow-up but all were undetectable on retesting. These transient positive tests probably represent false-positive test results.
The proportion of patients with a durable SVR did not differ between mono-infected patients receiving peginterferon alfa-2a alone (98.8%) or in combination with ribavirin (99.2%). Moreover, rates of durable SVR were also very high in patients with normal ALT levels (100%) or HIV-HCV coinfection (99.0%). 
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
HCV RNA was detected in the serum of 12 patients (0.9%) who obtained an SVR in their original studies. These patients showed recurrence of HCV RNA at a mean of 666 days (range, 391-1076 days) after completing treatment (Table 3) . Of those patients with recurrence of HCV RNA, 2 patients had been treated with peginterferon alfa-2a monotherapy, 9 had received peginterferon alfa-2a plus ribavirin, and one patient coinfected with HIV-HCV had received peginterferon alfa-2a monotherapy. Among these 12 patients, the risk factor for infection in the original trial before the long-term follow-up study was reported to be injection drug use in 7 patients and a blood transfusion in one patient. In 4 patients, the risk factor that led to HCV infection was undefined. Eight of the 12 patients with recurrence of HCV RNA had a rapid virologic response (HCV RNA Ͻ50 IU/mL by week 4) in their original trial. Three patients became HCV RNA undetectable by week 12, and one patient became HCV RNA undetectable for the first time between treatment weeks 12 and 24. One patient (patient 10; Table 3 ) with detectable HCV RNA at day 573 had unquantifiable HCV RNA at the same time point but quantifiable HCV RNA at day 645. A further patient (patient 11; Table 3 ) with detectable HCV RNA at day 655 had unquantifiable HCV RNA at the same time point and on retesting on day 689. The detectable HCV RNA with the qualitative assay probably represents a falsepositive result but, according to the definition specified in the protocol, this patient has been recorded as having recurrence of HCV RNA.
Among the 12 patients with recurrence of HCV RNA, there was no unique common baseline or treatment factor associated with the detection of HCV RNA during follow-up, including HCV genotype, sex, race, age, risk factor for infection, or baseline viral load. None of the patients with recurrence of HCV RNA in serum had cirrhosis before treatment with peginterferon alfa-2a. Nine patients (75%) had a high baseline viral load based on a 400,000 IU/mL cutoff and 7 patients (58%) had a high baseline viral load based on an 800,000 IU/mL cutoff. Three of the 12 patients (25%) with recurrence of HCV RNA showed evidence of virologic breakthrough during therapy in the original protocol (Table 4 ). Nine of the 12 patients with recurrence of HCV RNA had available ALT and aspartate aminotransferase (AST) values at or after the initial detection of HCV RNA. Three of the 9 had both ALT and AST values above the upper limit of normal, 2 had ALT values above the upper limit of normal, and one had an AST value above the upper limit of normal.
Repeated HCV RNA tests during the long-term follow-up study confirmed the recurrence of HCV RNA in 7 of the 12 patients. Repeat data were not available for the other 5 patients. Four of the 12 patients with recurrence of HCV RNA were shown to be infected with the same genotype as they had before treatment in the original study; this included 3 patients with genotype 1 and one patient with genotype 3. Paired samples were only available from one of these patients. Sequencing of the HCV genome to confirm that this was the strain the patient had before treatment was not performed.
Discussion
The present study represents the largest prospective cohort of patients followed up for the durability of SVR among patients previously treated for hepatitis C infection. The main finding of this long-term follow-up study in more than 1300 patients is that an SVR achieved with peginterferon alfa-2a, alone or in combination with ribavirin, is durable over the long-term and recurrence of HCV RNA is extremely rare. Overall, 99.1% of patients who achieved an SVR after treatment remained HCV RNA undetectable in serum at a mean of 3.9 years (range, 0.8 -7.1 years) of follow-up. An SVR is durable independent of the patient population; studies included HCV mono-infected patients, those with elevated or persistently normal ALT levels, and modestly immunocompromised HIV-HCV coinfected patients. Also, the durability of SVR appears to be unaffected by the type of treatment received. Achieving an SVR has great clinical significance and is associated with improvements in liver histology and health-related quality of life and with reductions in liver-related mortality. 1-6,8 -11 Based on the overall findings of this study, we suggest that it is an unnecessary burden to the individual as well as the health care system to retest all individuals with an SVR for the recurrence of HCV RNA indefinitely. We recommend that individuals who have achieved an SVR should have a single additional follow-up HCV RNA measurement performed to ensure that the negative HCV RNA result at 6 months posttreatment was not a "false negative" possibly due to faulty sample collection. If the second posttreatment HCV RNA measurement is negative, then no further RNA measurements need to be performed. However, we suggest that consideration should be given to a more prolonged HCV RNA retesting program for those individuals who show intermittent viral breakthrough during treatment (for at least a 3-year posttreatment period, based on our findings) or who may be considered at risk for reinfection. For any patient with a positive test result for HCV RNA, it is essential to repeat the test with a quantitative assay to confirm the recurrence of HCV RNA before concluding that the patient has reverted to a viremic state.
Ongoing monitoring of individuals for other morbidities associated with prior chronic hepatitis C should be based on the judgment of the physician. Current guidelines recommend monitoring patients at 6-or 12-month intervals for the development of hepatocellular carcinoma in cirrhotic patients who have achieved an SVR. 13 Approximately two-thirds of patients with recurrence of HCV RNA had laboratory data indicating an increased ALT and/or AST level at or after the time of recurrence of HCV RNA. All these patients had elevated ALT levels at the start of the original studies. Consequently, while raised ALT or AST values may indicate recurrence of HCV, it cannot be concluded that normal ALT or AST values are a surrogate for maintained clearance of HCV.
The question remains whether these cases reflect relapse or reinfection. Unfortunately, the paucity of paired samples in our study precludes the ability to draw a conclusion; therefore, it is not known whether patients who become HCV RNA detectable during follow-up experienced reinfection rather than virologic relapse. The results from the one patient who showed recurrence of HCV RNA, with transfusion as a risk factor for contracting HCV, might suggest a true late relapse. However, this patient was one of the 3 patients who had evidence of viral breakthrough during their original study (see Table 4 ; patient 9). In search of factors predicting recurrence of HCV RNA, no distinct pattern of baseline characteristics could be identified. Only one of the patients with recurrence of HCV RNA reported transfusion as a risk factor while, of the remaining 11 patients, 7 reported injection drug use as a risk factor and the remaining 4 reported unknown risk factor.
Eight of the 12 patients who became HCV RNA detectable were treated with peginterferon alfa-2a monotherapy or with doses or durations of combination therapy that are now considered less intensive than the standard of care for the given baseline patient characteristics. However, maintenance of SVR was shown to be similar among patients who received peginterferon alfa-2a monotherapy (98.8%) compared with combination therapy with peginterferon alfa-2a plus ribavirin (99.1%). Because the present literature shows no firm association of SVR durability with the potency of treatment, we conclude that durability of SVR is not related to the treatment modality.
The findings of the current study are comparable with those reported from other smaller studies with conventional interferon alone or in combination with ribavirin. In these reports, serum HCV RNA remained undetectable in 92% to 100% of patients who achieved an SVR, with 2 to 13 years of follow-up. 9, 10, [21] [22] [23] [31] [32] [33] In addition, a histologic improvement was seen in Ͼ94% of patients. 9, 33, 34 The majority of these studies involved small numbers of patients. However, based on the long-term results reported by McHutchison et al 22 in 492 sustained responders to interferon alfa-2b with or without ribavirin, the European Commission has adopted changes to EU labeling for interferon alfa-2b to indicate that SVR results in long-term clearance of the virus. 35 Three of the previously mentioned studies with conventional interferon with or without ribavirin also included small numbers of patients who were treated with pegylated interferon and ribavirin. 21, 31, 32 After approximately 2 to 3 years of follow-up, Ͼ99% of patients in these studies were HCV RNA negative, in keeping with the longer-term findings of our study. The durability of SVR observed in the current study with peginterferon alfa-2a is also comparable with that shown previously in a group of HIV-HCV coinfected patients who received any kind of interferon-based therapy 36 and in a cohort of 231 patients treated with peginterferon plus ribavirin followed for a median of 164 weeks. 37 After a mean follow-up period of 58 months, none of the 77 patients in that study showed detectable levels of serum HCV RNA.
The results of the present study are also consistent with those from a large review of data from more than 4000 patients treated with interferon or peginterferon with or without ribavirin from multiple studies from 1994 to 2008. The investigators concluded that only 3% of patients with an SVR showed evidence of a late recurrence of HCV RNA and that patients with an SVR should be considered noninfectious and cured of their infection. 38 The main limitations of the present study were that we could not assess the durability of SVR among patients who failed to return during follow-up. The protocol also excluded individuals who had a history or other evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator, unsuitable for the study. We therefore cannot exclude the possibility that patients who failed to return may have recurrence of HCV RNA and/or that some patients at a higher risk for recurrence may have been excluded from the study. We were also unable to conclude whether the recurrence of HCV RNA was a true late relapse or reinfection.
There is some debate as to whether the current interferon-based therapies for chronic hepatitis C infection result in complete eradication of HCV or whether small quantities may persist after therapy. SVR is defined as undetectable serum HCV RNA at 24 weeks after the end of therapy, and in this study this was determined with the qualitative Roche COBAS AMPLICOR HCV Test v2.0, which has a lower limit of detection of 50 IU/mL. Lower detection limits have recently been made available: 15 IU/mL with the Roche COBAS TaqMan HCV test 39 -41 Whether the use of a more sensitive assay would have affected our results is unknown and remains to be determined. It has been suggested that viral clearance from the liver may be a better marker of long-term response than eradication of serum HCV RNA; however, several studies reported no difference between the two. 9, 23, 33, 42 In a study of 2089 patients with chronic hepatitis C from 3 clinical trials, hepatic HCV RNA was found to correlate with serum HCV RNA in all cases. 43 Therefore, there appears to be no need to perform a liver biopsy in patients who achieve an SVR so that HCV RNA can be measured in liver tissue. Several small studies have described patients who achieved an SVR but have residual HCV RNA detected in peripheral blood mononuclear cells, lymphocytes, and macrophages with highly sensitive reverse transcription and nested polymerase chain reaction assays. 44, 45 Negative strands of HCV RNA have also been identified in the liver and peripheral blood mononuclear cells of some patients with SVR. 46, 47 Highly sensitive reverse transcription polymerase chain reaction assays are not currently standard diagnostic procedures, and whether these findings actually represent a replication-competent virus or have any clinical significance is not clear.
In conclusion, an SVR achieved with peginterferon alfa-2a, alone or in combination with ribavirin, is durable for at least 4 years after completion of therapy in more than 99% of patients and is independent of patient or treatment characteristics. These data suggest that the recurrence of HCV RNA is extremely rare in patients who achieve an SVR, and it now appears likely that such patients may be considered "cured" from a virologic standpoint. Although others have reported that eradication of HCV RNA is associated with an improvement in clinical outcome, 10,48 the risk of hepatocellular carcinoma remains a reality in patients with cirrhosis. As a result, patients with cirrhosis who achieve an SVR should continue to be monitored and screened for hepatocellular carcinoma on a regular basis.
